PancreaSeq® Genomic Classifier is a comprehensive molecular test for pancreatic cysts.
Pancreatic cysts are very common but only a small proportion of them are cancerous or can progress to cancer. While current imaging and laboratory approaches correctly diagnose many of cystic lesions, a significant proportion of them pose a diagnostic challenge. PancreaSeq® GC is a unique molecular test that utilizes revolutionary advances in pancreatic tumor genetics and sequencing technology to distinguish major types of pancreatic cystic lesions and predict their malignant potential to allow for the most optional patient management.
In a prospective study of more than 1,800 patients at 31 clinical centers in the US, the PancreaSeq test developed at the University of Pittsburgh surpassed currently used guidelines for correctly classifying potentially cancerous pancreatic cysts.
A molecular test called PancreaSeq accurately classifies pancreatic cysts as potentially cancerous or benign, according to a large, multi-center study led by University of Pittsburgh School of Medicine and UPMC researchers.